Advertisement

Corrigendum to “Hemodialysis and Biotransformation of Erythrocyte Epoxy Fatty Acids in Peripheral Tissue”

  • Tong Liu
    Affiliations
    Experimental and Clinical Research Center (ECRC), a joint institution of the Charité Medical Faculty and Max Delbrück Center (MDC) for Molecular Medicine, 13125 Berlin
    Search for articles by this author
  • Inci Dogan
    Affiliations
    LIPIDOMIX GmbH, Robert-Rössle-Str. 10, 13125 Berlin
    Search for articles by this author
  • Michael Rothe
    Affiliations
    LIPIDOMIX GmbH, Robert-Rössle-Str. 10, 13125 Berlin
    Search for articles by this author
  • Julius V. Kunz
    Affiliations
    Department of Nephrology and Medical Intensive Care, Charité - Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin
    Search for articles by this author
  • Felix Knauf
    Affiliations
    Department of Nephrology and Medical Intensive Care, Charité - Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin
    Search for articles by this author
  • Maik Gollasch
    Affiliations
    Department of Internal Medicine and Geriatrics, University Medicine Greifswald, 17475 Greifswald, Germany
    Search for articles by this author
  • Friedrich C. Luft
    Affiliations
    Experimental and Clinical Research Center (ECRC), a joint institution of the Charité Medical Faculty and Max Delbrück Center (MDC) for Molecular Medicine, 13125 Berlin
    Search for articles by this author
  • Benjamin Gollasch
    Correspondence
    Corresponding author. Experimental and Clinical Research Center (ECRC), a joint institution of the Charité Medical Faculty and Max Delbrück Center (MDC) for Molecular Medicine, Berlin 13125, Germany
    Affiliations
    Experimental and Clinical Research Center (ECRC), a joint institution of the Charité Medical Faculty and Max Delbrück Center (MDC) for Molecular Medicine, 13125 Berlin

    Department of Nephrology and Medical Intensive Care, Charité - Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin

    HELIOS Klinikum Berlin-Buch, Schwanebecker Chaussee 50, 13125 Berlin
    Search for articles by this author
Published:December 07, 2022DOI:https://doi.org/10.1016/j.plefa.2022.102521
      [Prostaglandins, Leukotrienes and Essential Fatty Acids, Volume 181, June 2022, 102453]
      DOI of original article: DOI: 10.1016/j.plefa.2022.102453
      The authors regret that an error occurred in the published version when editing the proofs, resulting in incorrect and redundant conclusions being listed in the "Highlights Section".
      After careful review, the highlight sentences should read as follows:
      • 1)
        Hemodialysis affects the arteriovenous differences of numerous erythro-LOX metabolites in the peripheral circulation.
      • 2)
        Erythro-epoxy fatty acids could contribute to cardiovascular risk.
      This error did not alter the data or conclusions of the article in any way.
      However, we also noticed that the layout of the tables has not been appropriately formatted. The tables that were originally submitted are now presented below.
      Tables 1, 2 and 3
      Table 1Characteristics of hemodialysis (HD) patients (n=12).
      HD patients
      Age (years)72±12
      Sex
       Male (n)9
       Female (n)3
      Body mass index (kg/m2)27±3.3
      Race (n)
      Caucasian = 12
      Cause of end-stage renal disease
       Focal segmental glomerulosclerosis6
       IgA nephropathy (n)1
       Renal amyloidosis1
       Hypertension (n)1
       Drug induced (n)1
       ADPKD (n)1
       Cystic kidneys1
      Complications
       Cardiovascular (n)12
      Notes: Data are presented as mean ± SD or frequencies.
      Table 2Effects of hemodialysis on hydroxy- and epoxy-metabolites in the CKD patients before (pre-HD) and at cessation (post-HD) of hemodialysis (n=12 each).
      Amount ng/gpre-HD Arterialpre-HD Venousp value, t test (# paired Wilcoxon test)pre-HD ΔA-Vpost-HD Arterialpost-HD Venousp value, t test (# paired Wilcoxon test)post-HD ΔA-V
      Panel A: Total metabolite levels.
      LOX metabolites
      5-HETE192.57 ±25.35198.56 ±32.710.511-5.99 ±30.53207.64 ±48.27173.93 ±31.810.00333.71 ±30.31
      8-HETE56.64 ±11.6856.70 ±9.360.991-0.05±15.8163.03 ±12.4556.56 ±9.360.0386.47 ±9.50
      9-HETE154.21 ±19.56159.42 ±18.960.388 #-5.21 ±25.47171.28 ±40.78136.62 ±24.320.00834.65 ±37.45
      11-HETE178.41 ±41.70179.03 ±46.160.948-0.61 ±31.52184.55 ±66.18171.73 ±57.790.3412.83 ±44.57
      12-HETE413.36 ±143.96469.21 ±325.750.638 #-55.85 ±297.34610.90 ±502.51352.44 ±141.850.071 #258.47 ±497.92
      15-HETE328.57 ±59.64331.87 ±65.680.844-3.30 ±56.56337.74 ±92.64306.33 ±85.330.09731.41 ±60.08
      4-HDHA115.75 ±40.87113.58 ±38.500.7542.17 ±23.38113.09 ±53.8986104.4464 ±43.31490.2638.6433 ±25.3880
      7-HDHA24.96 ±8.2225.15 ±4.150.388 #-0.19 ±7.0228.55 ±8.3422.08 ±5.510.0136.47 ±7.53
      8-HDHA29.24 ±9.9727.28 ±9.250.3731.95 ±7.2933.09 ±12.2026.17 ±10.390.0036.92 ±6.43
      10-HDHA20.09 ±6.2520.06 ±5.020.9880.02 ±4.8821.58 ±6.4518.34 ±6.650.0293.24 ±4.48
      11-HDHA37.79 ±24.8638.53 ±21.330.806-0.73 ±10.1734.92 ±28.6135.36 ±22.060.935-0.44 ±18.05
      13-HDHA45.76 ±17.6147.91 ±19.640.523-2.14 ±11.2446.84 ±22.5543.02 ±21.020.3013.82 ±12.21
      14-HDHA45.92 ±18.7348.43 ±15.560.53 #-2.51 ±16.6255.82 ±33.1137.95 ±10.820.034 #17.87 ±33.36
      16-HDHA58.53 ±27.0459.80±25.790.804-1.28 ±17.3856.87 ±28.8254.85 ±28.150.6632.02 ±15.62
      17-HDHA71.77 ±30.0970.33 ±27.140.7251.44 ±13.8070.20 ±31.5964.84 ±30.060.285.37 ±16.39
      20-HDHA143.35 ±63.29141.64 ±55.320.8681.71 ±34.73142.83 ±66.65130.52 ±60.980.25712.31 ±35.68
      5-HEPE14.85 ±6.9213.80 ±5.680.5191.05 ±5.4415.04 ±5.9112.94 ±5.660.1672.11 ±4.94
      8-HEPE2.09±0.852.20 ±0.600.631-0.11 ±0.772.56 ±0.891.85 ±0.720.0420.71 ±1.07
      9-HEPE5.35 ±2.365.14 ±1.650.740.22 ±2.196.44 ±2.454.45 ±1.910.021.99 ±2.54
      11-HEPE21.94 ±16.2523.29 ±13.880.655-1.35 ±10.1921.15 ±16.1620.49 ±13.960.8540.66 ±12.11
      12-HEPE38.22 ±21.8142.08 ±19.710.754 #-3.86 ±19.3349.19 ±44.1224.26 ±9.950.023 #24.93 ±44.72
      15-HEPE6.88 ±3.407.37 ±2.930.485-0.49 ±2.357.62 ±2.846.16 ±3.070.0561.46 ±2.37
      18-HEPE20.23 ±7.4319.27 ±6.610.5870.96 ±5.9520.58 ±7.4817.87 ±8.100.1082.71 ±5.38
      CYP ω/(ω−1) metabolites
      16-HETE11.35 ±4.5114.09 ±5.150.015 #-2.74 ±3.0311.13 ±5.2810.90 ±4.830.8770.23 ±5.03
      17-HETE0.23 ±0.080.26 ±0.070.16-0.03 ±0.060.23 ±0.070.21 ±0.060.3610.02 ±0.07
      18-HETE0.64 ±0.260.67 ±0.200.587-0.03 ±0.170.68 ±0.260.63 ±0.230.5460.04 ±0.24
      19-HETE0.32 ±0.110.35 ±0.140.136 #-0.03 ±0.070.35 ±0.170.28 ±0.100.182 #0.07 ±0.17
      20-HETE0.589 ±0.1380.63 ±0.240.695 #-0.05 ±0.150.64 ±0.150.53 ±0.180.030.10 ±0.14
      9-HODE95.46 ±20.97105.22 ±15.950.027-9.76 ±13.27112.39 ±38.9694.99 ±25.110.239 #17.40 ±43.98
      13-HODE108.45 ±26.10117.85 ±16.260.142-9.40 ±20.58131.67 ±51.38103.24 ±31.340.06 #28.43 ±58.70
      22-HDHA0.26 ±0.140.33 ±0.230.182 #-0.06 ±0.190.25 ±0.130.23 ±0.140.6160.02 ±0.15
      20-HEPE0.26 ±0.140.10 ±0.171 #0.01 ±0.040.05 ±0.070.05 ±0.100.893 #0.00 ±0.08
      CYP epoxy-metabolites
      5,6-EET62.22 ±68.3069.46 ±65.900.308 #-7.24 ±21.7991.36 ±99.9956.52 ±63.890.347 #34.84 ±83.99
      8,9-EET62.07 ±16.1065.90 ±13.950.524-3.83 ±20.1776.50 ±22.0463.37 ±14.100.06713.13 ±22.35
      11,12-EET69.88 ±14.4175.19 ±19.910.513-5.30 ±27.1784.18 ±25.5169.94 ±15.930.136 #14.24 ±28.98
      14,15-EET92.07 ±25.43103.57 ±31.770.306-11.49 ±37.08109.32 ±40.8694.90 ±24.380.182 #14.41 ±42.81
      5,6-DHET2.57 ±0.602.84 ±0.760.084 #-0.27 ±0.472.68 ±0.862.24 ±0.500.0850.43 ±0.80
      8,9-DHET3.44 ±1.643.66 ±1.670.209 #-0.21 ±0.793.48 ±1.623.03 ±1.500.099 #0.45 ±1.15
      11,12-DHET1.66 ±0.641.66 ±0.630.875 #0.00 ±0.441.76 ±0.481.49 ±0.470.0040.27 ±0.26
      14,15-DHET2.29 ±0.352.29 ±0.380.956-0.01 ±0.482.35 ±0.352.14 ±0.270.1770.21 ±0.49
      9,10-EpOME37.19 ±15.8940.17 ±11.390.386-2.99 ±11.4654.47 ±28.7140.01 ±17.560.12814.46 ±30.45
      12,13-EpOME39.69 ±12.9143.09 ±8.730.385-3.40 ±13.0255.17 ±21.0243.09 ±13.080.071 #12.08 ±24.98
      9,10-DiHOME1.98 ±1.282.13 ±1.430.638 #-0.15 ±0.742.72 ±2.062.36 ±1.930.638 #0.35 ±2.03
      12,13-DiHOME3.49 ±1.353.36 ±1.560.583 #0.13 ±1.044.50 ±2.834.57 ±2.950.347 #-0.07 ±2.67
      7,8-EDP39.28 ±19.8640.07 ±18.500.695 #-0.79 ±21.0744.29 ±16.3939.12 ±13.120.2415.16 ±14.42
      10,11-EDP18.95 ±8.5620.22 ±7.140.613-1.27 ±8.4525.07 ±9.4518.32 ±5.640.036.75 ±9.39
      13,14-EDP17.88 ±9.9919.76 ±10.120.569-1.88 ±11.1018.31 ±7.9814.44 ±4.460.1443.88 ±8.54
      16,17-EDP32.72 ±16.51336.67 ±15.080.474-3.96 ±18.4827.36 ±14.5421.28 ±9.220.182 #6.08 ±14.78
      19,20-EDP23.01 ±10.2125.17 ±10.130.48 #-2.16 ±12.0032.01 ±11.7422.38 ±6.480.019 #9.63 ±12.86
      7,8-DiHDPA1.15 ±0.501.29 ±0.470.262-0.14 ±0.401.32 ±0.711.22 ±0.480.5960.10 ±0.62
      10,11-DiHDPA0.76 ±0.170.74 ±0.140.7130.02 ±0.170.75 ±0.190.70 ±0.170.4490.05 ±0.21
      13,14-DiHDPA0.85 ±0.330.77 ±0.210.4640.08 ±0.380.87 ±0.390.89 ±0.380.859-0.02 ±0.31
      16,17-DiHDPA0.48 ±0.160.49 ±0.120.831-0.01 ±0.150.48 ±0.190.479 ±0.110.8980.01 ±0.16
      19,20-DiHDPA1.19 ±0.431.09 ±0.280.4020.10 ±0.391.28 ±0.351.05 ±0.250.1080.23 ±0.45
      5,6-EEQnsnsnsnsnsnsnsns
      8,9-EEQ3.10 ±2.482.69 ±1.170.58 #0.40 ±2.454.22 ±2.602.76 ±1.400.028 #1.46 ±2.12
      11,12-EEQ3.64 ±2.593.68 ±2.020.875 #-0.04 ±3.044.89 ±1.723.58 ±1.290.0291.30 ±1.80
      14,15-EEQ2.83 ±1.682.75 ±1.410.814 #0.08 ±2.033.78 ±1.712.54 ±0.950.0321.25 ±1.76
      17,18-EEQ4.74 ±4.034.09 ±2.080.937 #0.65 ±3.027.42 ±6.134.67 ±3.850.071 #2.75 ±5.54
      5,6-DiHETE2.61 ±0.981.71 ±0.460.0110.90 ±1.032.21 ±0.732.09 ±0.490.875 #0.12 ±0.83
      8,9-DiHETE0.22 ±0.170.17 ±0.060.272 #0.05 ±0.140.21 ±0.090.19 ±0.050.695 #0.02 ±0.10
      11,12-DiHETE3.80 ±2.553.56 ±1.680.7770.24 ±2.905.30 ±2.664.70±3.490.388 #0.60 ±4.32
      14,15-DiHETE0.13 ±0.100.11 ±0.040.937 #0.020 ±0.100.05 ±0.070.05 ±0.100.041 #0.04 ±0.06
      17,18-DiHETE0.44 ±0.170.39 ±0.110.2190.05 ±0.140.43 ±0.160.45 ±0.221 #-0.02 ±0.22
      Panel B: Free metabolite levels.
      LOX metabolites
      5-HETE2.50 ±1.672.51 ±2.930.638 #-0.01 ±3.702.42 ±1.421.47 ±1.600.071 #0.95 ±1.84
      8-HETE2.38 ±0.611.77 ±0.460.0060.61 ±0.622.38 ±0.851.39 ±0.560.0030.99\ ±0.88
      9-HETE2.49 ±1.301.75 ±0.810.0110.74 ±0.841.99 ±0.871.28 ±0.600.0230.71 ±0.88
      11-HETE3.10 ±1.212.29 ±1.060.012 #0.81 ±0.912.76 ±1.191.76 ±0.650.0161.00 ±1.17
      12-HETE544.04 ±231.17425.17 ±210.460.077118.86 ±211.26555.84 ±336.12336.43 ±213.050.015219.41±252.60
      15-HETE6.88 ±1.865.21 ±2.070.0031.66 ±1.557.45 ±2.704.50 ±1.790.0012.95 ±2.21
      4-HDHA0.23 ±0.110.20 ±0.090.1690.03 ±0.070.21 ±0.090.13 ±0.070.0010.08 ±0.06
      7-HDHA0.38 ±0.150.34 ±0.280.289 #0.04 ±0.250.28 ±0.180.16 ±0.050.01 #0.12 ±0.16
      8-HDHA4.17 ±3.733.59 ±4.050.433 #0.59 ±1.873.74 ±3.542.02 ±1.930.0351.72 ±2.37
      10-HDHA1.41 ±0.861.13 ±0.780.06 #0.28 ±0.441.11 ±0.650.69 ±0.400.0170.42 ±0.50
      11-HDHA5.39 ±3.804.41 ±3.200.099 #0.98±1.803.57 ±2.412.18 ±1.470.0311.38 ±1.87
      13-HDHA0.82 ±0.670.67 ±0.730.05 #0.16 ±0.250.52 ±0.330.32 ±0.160.003 #0.20 ±0.24
      14-HDHA30.72 ±21.1325.10 ±18.550.117 #5.62 ±11.1623.18 ±17.7514.14 ±9.380.0439.04 ±13.07
      16-HDHA2.21 ±2.641.77 ±3.690.06 #0.44 ±4.673.68 ±5.341.47 ±2.160.002 #2.21 ±3.28
      17-HDHA1.84 ±1.021.40 ±0.820.028 #0.44 ±0.591.46 ±0.700.86 ±0.400.0010.60 ±0.47
      20-HDHA2.27 ±1.061.84 ±1.060.0390.44 ±0.642.39 ±1.381.35 ±0.600.003 #1.03 ±0.99
      5-HEPE0.52 ±0.290.50 ±0.610.347 #0.02 ±0.690.51 ±0.480.23 ±0.170.041 #0.28 ±0.48
      8-HEPE0.11 ±0.070.07 ±0.040.002 #0.03 ±0.040.09 ±0.070.05 ±0.020.003 #0.04 ±0.06
      9-HEPE0.32 ±0.270.21 ±0.130.006 #0.11 ±0.170.25 ±0.220.13 ±0.040.006 #0.12 ±0.21
      11-HEPE0.70 ±0.550.49 ±0.430.008 #0.21 ±0.200.56 ±0.360.34 ±0.210.003 #0.21 ±0.19
      12-HEPE43.51 ±25.8735.57 ±23.180.1027.94 ±15.4231.16 ±21.7818.21 ±11.770.03412.95 ±17.70
      15-HEPE0.42 ±0.240.32 ±0.170.023 #0.09 ±0.140.35 ±0.210.23 ±0.080.019 #0.12 ±0.18
      18-HEPE0.60 ±0.280.41 ±0.140.0130.19 ±0.220.57 ±0.330.33 ±0.120.003 #0.24 ±0.28
      CYP ω/(ω−1) metabolites
      16-HETE0.09 ±0.030.08 ±0.020.0840.01 ±0.020.10 ±0.030.08 ±0.010.272 #0.01 ±0.03
      17-HETEnsnsns #nsnsns #nsns
      18-HETE0.04 ±0.010.04 ±0.010.7980.00 ±0.010.045 ±0.020.04 ±0.020.350.01 ±0.03
      19-HETE0.01 ±0.010.00±0.011 #00.01 ±0.020.01 ±0.021 #0.00 ±0.01
      20-HETE0.07 ±0.070.13 ±0.080.013 #-0.06 ±0.060.06 ±0.060.10 ±0.090.131 #-0.04 ±0.07
      9-HODE24.96 ±16.2145.28 ±99.250.209 #-20.31 ±85.3414.67±8.4512.19±8.950.084 #2.48 ±7.13
      13-HODE19.85 ±10.4737.06 ±77.530.272 #-17.21 ±71.5712.38 ±7.039.17 ±6.280.041 #3.20 ±5.05
      22-HDHA0.08 ±0.070.07 ±0.040.583 #0.01 ±0.080.05 ±0.020.04 ±0.020.534 #0.00 ±0.02
      20-HEPE0.03 ±0.040.03 ±0.050.866 #0.00 ±0.060.01 ±0.030.03 ±0.040.138 #-0.02 ±0.03
      CYP epoxy-metabolites
      5,6-EET0.67 ±0.330.56 ±0.330.388 #0.11 ±0.441.01 ±0.490.80 ±0.330.239 #0.21 ±0.58
      8,9-EET1.37 ±0.771.43 ±1.020.846-0.05 ±0.891.48 ±0.881.41 ±0.680.8160.07 ±0.95
      11,12-EET0.80 ±0.310.59 ±0.260.099 #0.22 ±0.411.19 ±0.600.94 ±0.380.2880.25 ±0.78
      14,15-EET0.86 ±0.330.67 ±0.330.158 #0.19 ±0.431.41 ±0.621.02 ±0.320.090.39 ±0.73
      5,6-DHET0.03 ±0.020.03 ±0.010.6070.00 ±0.020.03 ±0.010.03 ±0.020.06 #0.01 ±0.02
      8,9-DHET0.09 ±0.020.09 ±0.030.6530.00 ±0.030.08 ±0.020.08 ±0.020.347 #0.00 ±0.02
      11,12-DHET0.07±0.040.07 ±0.040.388 #0.00 ±0.010.07 ±0.050.06 ±0.030.158 #0.01 ±0.03
      14,15-DHET0.09 ±0.030.09 ±0.040.209 #-0.01 ±0.020.09 ±0.040.08 ±0.030.272 #0.01 ±0.03
      9,10-EpOME4.02 ±1.615.90 ±8.910.814 #-1.88 ±8.524.25 ±2.094.28 ±2.380.638 #-0.02 ±2.16
      12,13-EpOME4.46 ±1.806.87 ±10.610.814 #-2.41 ±10.194.42 ±1.844.68 ±2.430.68-0.26 ±2.13
      9,10-DiHOME0.912 ±0.491.16 ±0.880.388 #-0.24 ±0.690.83 ±0.691.03 ±0.910.023 #-0.21 ±0.27
      12,13-DiHOME1.46 ±0.771.90 ±1.330.308 #-0.44 ±1.251.55 ±1.301.92 ±1.680.136 #-0.37 ±0.51
      7,8-EDP0.32 ±0.140.24 ±0.140.158 #0.08 ±0.170.39 ±0.240.29 ±0.150.1160.09 ±0.19
      10,11-EDP0.14 ±0.060.14 ±0.090.638 #0.00 ±0.090.18 ±0.110.15 ±0.070.388 #0.03 ±0.09
      13,14-EDP0.13 ±0.070.13 ±0.120.937 #0.00 ±0.100.13 ±0.090.12 ±0.080.53 #0.01 ±0.08
      16,17-EDP0.24 ±0.090.21 ±0.110.367 #0.03 ±0.100.27 ±0.160.22 ±0.120.182 #0.05 ±0.13
      19,20-EDP0.20 ±0.080.18 ±0.100.48 #0.02 ±0.110.19 ±0.110.21 ±0.080.568-0.02 ±0.10
      7,8-DiHDPA0.03 ±0.010.03 ±0.010.2250.00 ±0.010.05 ±0.010.03 ±0.010.5650.00 ±0.01
      10,11-DiHDPA0.03 ±0.020.03 ±0.020.05 #00.03 ±0.020.02 ±0.020.308 #0.00 ±0.01
      13,14-DiHDPA0.04 ±0.010.04 ±0.010.347 #0.00 ±0.010.04 ±0.010.04 ±0.010.477 #0.00 ±0.01
      16,17-DiHDPA0.05 ±0.010.05 ±0.010.1990.00 ±0.010.05 ±0.010.05 ±0.010.7870.00 ±0.01
      19,20-DiHDPA0.31 ±0.160.29 ±0.170.638 #0.02 ±0.170.47 ±0.370.31 ±0.180.136 #0.16 ±0.36
      5,6-EEQnsnsnsnsnsnsnsns
      8,9-EEQ0.13 ±0.070.09 ±0.050.1210.03 ±0.070.120 ±0.140.17 ±0.080.583 #0.03 ±0.14
      11,12-EEQ0.10 ±0.090.11 ±0.080.814 #0.00 ±0.110.17 ±0.130.11 ±0.070.388 #0.05 ±0.13
      14,15-EEQ0.10 ±0.070.09 ±0.060.814 #0.01 ±0.080.16 ±0.120.13 ±0.080.814 #0.03 ±0.14
      17,18-EEQ0.13 ±0.100.13 ±0.100.875 #0.00 ±0.110.21 ±0.170.12 ±0.050.099 #0.09 ±0.16
      5,6-DiHETE0.07 ±0.030.06 ±0.030.6410.01 ±0.050.08 ±0.040.05 ±0.030.0620.03 ±0.05
      8,9-DiHETE0.01 ±0.010.01 ±0.010.109 #00.01 ±0.010.01 ±0.011 #0.00 ±0.01
      11,12-DiHETE0.02 ±0.010.02 ±0.010.327 #0.00 ±0.010.02 ±0.010.01 ±0.000.0230.01 ±0.01
      14,15-DiHETE0.01 ±0.010.01 ±0.010.875 #00.02 ±0.000.01 ±0.000.1980.00 ±0.01
      17,18-DiHETE0.07 ±0.020.07 ±0.030.9860.00 ±0.030.08 ±0.030.07 ±0.030.695 #0.00 ±0.03
      Notes: A, arterial blood; V, venous blood. A-V difference; arteriovenous difference. Mean±SD.
      Table 3Effects of hemodialysis on epoxides and their respective diol ratios in the CKD patients before (pre-HD) and at cessation (post-HD) of hemodialysis (n=12 each).
      Amount ng/gpre-HD Arterialpre-HD Venousp value, t test

      (# paired Wilcoxon test)
      pre-HD ΔA-Vpost-HD Arterialpost-HD Venousp value, t test (# paired Wilcoxon test)pre-HD ΔA-V
      Panel A: Total metabolite levels.
      5,6-EET + 5,6-DHET64.79 ±67.7972.30 ±68.410.308 #-7.51 ±21.7294.04 ±99.6958.76 ±63.490.308 #35.28 ±83.82
      8,9-EET + 8,9-DHET65.52 ±15.8869.56 ±14.810.509-4.04 ±20.5379.98 ±22.5566.40 ±13.530.05513.58 ±21.94
      11,12-EET + 11,12-DHET71.55 ±14.3776.85 ±20.730.513-5.30 ±27.1885.94 ±25.6971.43 ±15.930.099 #14.51 ±29.01
      14,15-EET + 14,15-DHET94.36 ±25.30105.86 ±33.030.306-11.50 ±37.09111.66 ±40.9797.05 ±24.400.182 #14.62 ±43.00
      12,13-EpOME + 12,13-DiHOME43.18 ±13.4346.45 ±9.570.399-3.27 ±12.9259.67 ±23.2347.66 ±15.270.084 #12.01 ±26.84
      9,10-EpOME + 9,10-DiHOME39.16 ±16.9042.30 ±13.100.374-3.14 ±11.7457.19 ±30.6242.38 ±19.350.099 #14.81 ±32.19
      5,6-EEQ + 5,6-DiHETE2.62 ±0.991.71 ±0.480.011 #0.90 ±1.032.22 ±0.732.10 ±0.480.875 #0.12 ±0.83
      8,9-EEQ + 8,9-DiHETE3.31 ±2.642.87 ±1.250.814 #0.45 ±2.564.43 ±2.672.95 ±1.430.028 #1.47 ±2.19
      11,12-EEQ + 11,12-DiHETE7.43 ±4.777.24 ±3.220.9030.20 ±5.5210.19 ±3.678.29 ±3.820.2561.90 ±5.49
      14,15-EEQ + 14,15-DiHETE2.96 ±1.752.87 ±1.490.754 #0.10 ±2.073.94 ±1.762.66 ±0.990.031.29 ±1.79
      17,18-EEQ + 17,18-DiHETE5.19 ±4.144.48 ±2.190.937 #0.70 ±3.157.86 ±6.185.12 ±3.800.136 #2.74 ±5.63
      7,8-EDP + 7,8-DiHDPA40.43 ±20.0741.36 ±19.510.884-0.92 ±21.3745.61 ±16.8240.35 ±13.320.2435.26 ±14.78
      10,11-EDP + 10,11-DiHDPA19.71 ±8.6720.96 ±7.450.622-1.25 ±8.5325.82 ±9.4719.03 ±5.580.0296.79 ±9.37
      13,14-EDP + 13,14-DiHDPA18.73 ±10.2720.53 ±10.580.594-1.80 ±11.3619.18 ±8.0215.32 ±4.450.1513.86 ±8.67
      16,17-EDP + 16,17-DiHDPA33.20 ±16.6037.17 ±15.810.475-3.97 ±18.5927.83 ±14.5121.75 ±9.180.182 #6.09 ±14.80
      19,20-EDP + 19,20-DiHDPA24.20 ±10.5726.26 ±10.680.48 #-2.06 ±12.1933.29 ±11.8123.43 ±6.570.015 #9.86 ±13.00
      Ratio (9,10-DiHOME+12,13-DiHOME)/(9,10-EpOME+12,13-EpOME)0.08 ±0.040.06 ±0.030.583 #0.01 ±0.040.06 ±0.020.08 ±0.030.053-0.02±0.03
      Ratio(5,6-DHET+8,9-DHET+11,12-DHET+14,15-DHET)/(5,6-EET+8,9-EET +11,12 EET +14,15-EET)0.04 ±0.020.04 ±0.010.53 #0.00 ±0.020.03 ±0.010.03 ±0.010.510.00 ±0.01
      Ratio(5,6-DiHETE+8,9-DiHETE+11,12-DiHETE+14,15-DiHETE+17,18-DiHETE)/(5,6-EEQ+ 8,9-EEQ+11,12-EEQ+14,15-EEQ+17,18-EEQ)0.57 ±0.190.48 ±0.200.1650.09 ±0.210.45 ±0.190.67 ±0.470.117 #-0.22 ±0.46
      Ratio(7,8-DiHDPA+10,11-DiHDPA +13,14-DiHDPA+16,17-DiHDPA+19,20-DiHDPA)/(7,8-EDP+10,11-EDP+13,14-EDP+16,17-EDP+19,20-EDP)0.04 ±0.020.03 ±0.010.583 #0.00 ±0.020.03 ±0.010.04 ±0.020.199-0.01 ±0.01
      9,10-DiHOME/9,10-EpOME0.05 ±0.030.05 ±0.020.6150.00 ±0.020.05 ±0.020.05 ±0.020.186-0.01 ±0.02
      12,13-DiHOME/12,13-EpOME0.10 ±0.050.08 ±0.030.2750.02 ±0.050.08 ±0.030.102 ±0.050.05 #-0.02 ±0.04
      5,6-DHET/5,6-EET0.11 ±0.100.09 ±0.070.48 #0.02±0.070.13 ±0.110.11 ±0.100.308 #0.02 ±0.12
      8,9-DHET/8,9-EET0.06 ±0.040.06 ±0.030.638 #0.01 ±0.020.05 ±0.020.05 ±0.030.875 #-0.01 ±0.03
      11,12-DHET/11,12-EET0.031 ±0.010.02 ±0.010.638 #0.00 ±0.010.02 ±0.010.02 ±0.010.9950.00 ±0.01
      14,15-DHET/14,15-EET0.03 ±0.010.02 ±0.010.4630.00 ±0.010.02 ±0.010.02 ±0.010.9370.00 ±0.01
      5,6-DiHETE/5,6-EEQ1940.29 ±1425.661107.48 ±699.940.003 #832.81 ±848.101242.35±1220.111551.99±1013.060.33-309.64 ±1052.11
      8,9-DiHETE/8,9-EEQ0.08 ±0.030.07 ±0.020.3840.01 ±0.030.06 ±0.020.08 ±0.030.042-0.03 ±0.04
      11,12-DiHETE/11,12-EEQ1.15 ±0.971.17 ±0.980.388 #-0.02 ±0.741.14 ±0.691.44 ±1.260.638 #-0.30 ±1.36
      14,15-DiHETE/14,15-EEQ0.05 ±0.020.05 ±0.020.8590.00 ±0.030.05 ±0.020.05 ±0.020.7720.00 ±0.03
      17,18-DiHETE/17,18-EEQ0.14 ±0.080.12 ±0.060.3240.02 ±0.060.09 ±0.060.14 ±0.080.032-0.06 ±0.08
      7,8-DiHDPA/7,8-EDP0.04 ±0.020.04 ±0.010.638 #0.00 ±0.010.03 ±0.010.03 ±0.020.308 #0.00 ±0.01
      10,11-DiHDPA/10,11-EDP0.0477 ±0.02500.0421 ±0.02020.433 #0.0056 ±0.02060.0342 ±0.01490.0427 ±0.01790.187-0.0085 ±0.0208
      13,14-DiHDPA/13,14-EDP0.06 ±0.030.05 ±0.030.347 #0.01 ±0.030.06 ±0.030.07 ±0.050.388 #-0.01 ±0.03
      16,17-DiHDPA/16,17-EDP0.02 ±0.020.02 ±0.010.48 #0.00 ±0.020.03 ±0.020.03 ±0.020.8530.00 ±0.02
      19,20-DiHDPA/19,20-EDP0.06±0.020.05 ±0.020.209 #0.01 ±0.020.04 ±0.010.05 ±0.010.373-0.01 ±0.02
      Panel B: Free metabolite levels.
      11,12-EET + 11,12-DHET0.88 ±0.300.66 ±0.250.099 #0.22 ±0.411.26 ±0.611.00 ±0.390.280.26 ±0.80
      14,15-EET + 14,15-DHET0.95 ±0.320.76 ±0.320.136 #0.19 ±0.441.50 ±0.631.10 ±0.330.0910.40 ±0.74
      5,6-EET + 5,6-DHET0.70 ±0.3200.388 #0.11 ±0.441.04 ±0.4900.272 #0.21 ±0.58
      8,9-EET + 8,9-DHET1.46 ±0.760.12 ±0.080.83-0.06 ±0.871.56 ±0.880.13 ±0.070.8170.07 ±0.95
      9,10-EpOME + 9,10-DiHOME4.94 ±1.860.59 ±0.330.875 #-2.11 ±9.185.08 ±2.400.83 ±0.320.739-0.230 ±2.34
      12,13-EpOME + 12,13-DiHOME5.92 ±2.411.51 ±1.001 #-2.85 ±11.335.97±2.501.49±0.680.754 #-0.63 ±2.46
      5,6-EEQ + 5,6-DiHETE00.11 ±0.061 #000.15 ±0.081 #0
      8,9-EEQ + 8,9-DiHETE0.14 ±0.080.20 ±0.120.158 #0.04 ±0.070.21 ±0.140.20 ±0.080.583 #0.04 ±0.14
      11,12-EEQ + 11,12-DiHETE0.12 ±0.090.27 ±0.140.754 #0.00 ±0.110.19 ±0.140.33 ±0.150.272 #0.06 ±0.14
      14,15-EEQ + 14,15-DiHETE0.12 ±0.070.10 ±0.050.638 #0.01 ±0.080.18 ±0.120.17 ±0.070.814 #0.03 ±0.14
      17,18-EEQ + 17,18-DiHETE0.20 ±0.120.12 ±0.100.814 #0.00 ±0.120.29 ±0.180.07 ±0.040.158 #0.09 ±0.17
      7,8-EDP + 7,8-DiHDPA0.35 ±0.140.17 ±0.120.117 #0.08 ±0.170.42 ±0.250.16 ±0.090.1320.09 ±0.19
      10,11-EDP + 10,11-DiHDPA0.17 ±0.060.27 ±0.110.695 #0.00 ±0.090.21 ±0.150.27 ±0.120.2980.03 ±0.09
      13,14-EDP + 13,14-DiHDPA0.17 ±0.070.47 ±0.220.937 #0.00 ±0.100.17 ±0.100.52 ±0.220.6280.01 ±0.08
      16,17-EDP + 16,17-DiHDPA0.29 ±0.090.17 ±0.090.53 #0.03 ±0.100.32 ±0.160.18 ±0.070.182 #0.05 ±0.13
      19,20-EDP + 19,20-DiHDPA0.51 ±0.190.34 ±0.140.5840.04 ±0.230.66 ±0.390.34 ±0.170.1760.15 ±0.35
      Ratio(5,6-DHET+8,9-DHET+11,12-DHET+14,15-DHET)/(5,6-EET+8,9-EET +11,12 EET +14,15-EET)0.11 ±0.110.14 ±0.090.308 #-0.01 ±0.070.07 ±0.050.08 ±0.040.695 #0.00 ±0.05
      Ratio(5,6-DiHETE+8,9-DiHETE+11,12-DiHETE+14,15-DiHETE+17,18-DiHETE)/(5,6-EEQ+ 8,9-EEQ+11,12-EEQ+14,15-EEQ+17,18-EEQ)0.49±0.210.17±0.100.556-0.06 ±0.330.34 ±0.130.09 ±0.040.6380.02 ±0.14
      Ratio (9,10-DiHOME+12,13-DiHOME)/(9,10-EpOME+12,13-EpOME)0.29 ±0.120.55 ±0.330.305-0.05 ±0.170.29 ±0.180.32 ±0.080.183-0.05 ±0.11
      Ratio(7,8-DiHDPA+10,11-DiHDPA +13,14-DiHDPA+16,17-DiHDPA+19,20-DiHDPA)/(7,8-EDP+10,11-EDP+13,14-EDP+16,17-EDP+19,20-EDP)0.50 ±0.190.61 ±0.360.308 #-0.11 ±0.340.70 ±0.600.56 ±0.390.583 #0.14 ±0.71
      9,10-DiHOME/9,10-EpOME0.24 ±0.130.27 ±0.150.439-0.03 ±0.130.21 ±0.130.24 ±0.120.164-0.04 ±0.08
      12,13-DiHOME/12,13-EpOME0.34 ±0.13010.4102 ±0.15980.288-0.0710 ±0.22010.3751 ±0.24040.4241 ±0.22530.308 #-0.0490 ±0.1422
      5,6-DHET/5,6-EET0.07 ±0.050.07 ±0.040.48 #0.00 ±0.050.04 ±0.030.04 ±0.030.583 #0.00±0.02
      8,9-DHET/8,9-EET0.16 ±0.240.20 ±0.330.388 #-0.04 ±0.320.10 ±0.130.09 ±0.101 #0.01 ±0.06
      11,12-DHET/11,12-EET0.13 ±0.150.25 ±0.240.48 #-0.01 ±0.110.08 ±0.070.12 ±0.080.388 #0.00 ±0.07
      14,15-DHET/14,15-EET0.15 ±0.167.05 ±9.620.182 #-0.02 ±0.130.08 ±0.075.31 ±3.030.433 #-0.014 ±0.07
      5,6-DiHETE/5,6-EEQ001 #0001 #0
      8,9-DiHETE/8,9-EEQ0.081 ±0.160.07 ±0.141 #0.00 ±0.090.04 ±0.090.04 ±0.081 #0.00±0.05
      11,12-DiHETE/11,12-EEQ0.29 ±0.190.26 ±0.280.638 #0.03 ±0.280.21 ±0.260.13 ±0.050.239 #0.08 ±0.25
      14,15-DiHETE/14,15-EEQ0.17 ±0.090.74 ±0.380.695 #-0.07 ±0.260.12 ±0.060.70 ±0.430.937 #0.00 ±0.11
      17,18-DiHETE/17,18-EEQ0.92 ±0.888.77 ±11.800.875 #0.18 ±1.030.49 ±0.306.60 ±3.540.308 #-0.22 ±0.55
      7,8-DiHDPA/7,8-EDP0.14 ±0.130.15 ±0.090.347 #-0.01 ±0.130.11 ±0.080.14 ±0.070.182 #-0.03 ±0.08
      10,11-DiHDPA/10,11-EDP0.23 ±0.250.24 ±0.170.158 #-0.01 ±0.160.19 ±0.170.18 ±0.100.875 #0.01 ±0.15
      13,14-DiHDPA/13,14-EDP0.53 ±0.440.61 ±0.450.638 #-0.08 ±0.620.46 ±0.430.44 ±0.220.308 #0.02 ±0.44
      16,17-DiHDPA/16,17-EDP0.26 ±0.150.30 ±0.130.308 #-0.05 ±0.150.23 ±0.120.29 ±0.180.48 #-0.06 ±0.21
      19,20-DiHDPA/19,20-EDP1.81 ±1.151.97 ±1.290.53 #-0.16 ±0.953.53 ±3.361.73 ±1.350.084 #1.80 ±3.37
      Notes: Ratios were estimated using total concentrations of epoxides and diols in RBCs. A, arterial blood; V, venous blood. A-V difference; arteriovenous difference. Mean±SD.
      The authors all agree to the publication of this corrigendum, and are grateful to the Editor of Prostaglandins, Leukotrienes and Essential Fatty Acids for allowing them the opportunity to publish this. The authors would like to apologise for any inconvenience caused.

      Linked Article

      • Hemodialysis and biotransformation of erythrocyte epoxy fatty acids in peripheral tissue
        Prostaglandins, Leukotrienes and Essential Fatty AcidsVol. 181
        • Preview
          Abbreviation: AV, arteriovenous; CKD, chronic kidney disease; ESRD, end-stage renal disease; AA, arachidonic acid; EpOMEs, epoxyoctadecenoic acids; HETE, hydroxyeicosatetraenoic acid; LOX, lipoxygenase; PUFA, polyunsaturated fatty acid; CYP450, cytochrome P450; EDP, epoxydocosapentaenoic acid; EEQ, epoxyeicosatetraenoic acid; EET, epoxyeicosatrienoic acid; HDHA, hydroxydocosahexaenoic acid; HEPE, hydroxyeicosapentaenoic acid; DHETs, dihydroxyeicosatrienoic acids; DiHOMEs, dihydroxyctadecenoic acids; DiHDPAs, dihydroxydocosapentaenoic acids; DiHETEs, dihydroxyeicosatetraenoic acids; LOX, lipoxygenase; HD, hemodialysis; sEH, soluble epoxide hydrolase; EPA, eicosapentaenoic acid; LA, linolenic acid; DHA, docosahexaenoic acid; SD, standard deviation; ADPKD, autosomal dominant polycystic kidney disease; ATP, adenosine triphosphate; PPARs, peroxisome proliferator-activated receptors; ESAs, erythropoiesis-stimulating agents
        • Full-Text
        • PDF